<DOC>
	<DOC>NCT02885376</DOC>
	<brief_summary>The primary objective of this study is to determine the efficacy of Dentoxol® mouthrinse in reducing the severity of oral mucositis secondary to radiation therapy for head and neck cancer.</brief_summary>
	<brief_title>Study of Dentoxol® Mouthrinse for Oral Mucositis</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Planned to receive radiation therapy for cancer of the oral cavity, oropharynx, nasopharynx, hypopharynx or larynx, with or without concomitant chemotherapy. Planned to receive at least 5000cGy radiation therapy to at least 2 of 12 prespecified areas in the oral cavity Unable to give written informed consent Known allergy/intolerance to any component of the study rinse or placebo Planning to use any contraindicated medications during the study period (pain medications are allowed) Age below 18 years Pregnant or nursing (If the patient is a woman of childbearing potential, a pregnancy test must be performed within fourteen days before enrollment in the study)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mucositis</keyword>
</DOC>